[SC TO-C] LAVA Therapeutics N.V. Tender Offer Communication

Rhea-AI Filing Summary

On 4 Aug 2025, XOMA Royalty Corp. filed a Schedule TO-C announcing its intention to launch a third-party tender offer for 100 % of LAVA Therapeutics N.V. (LVTX) ordinary shares. The communication is strictly pre-commencement; no shares can yet be tendered. The bid will be made pursuant to a Share Purchase Agreement signed 3 Aug 2025; full terms (price, consideration mix, CVR mechanics, timing) will appear in a forthcoming Schedule TO, while LAVA will respond with a Schedule 14D-9.

The filing attaches a joint press release (Ex. 99.1) and contains extensive forward-looking-statement warnings. Key risks flagged include potential competing bids, regulatory or legal challenges, failure to meet closing conditions, and uncertainty over any Contingent Value Right payments. Until the formal offer materials are filed with the SEC, investors are urged not to take action and to review the official documents once available at www.sec.gov or XOMA’s investor site.

Positive

• Upcoming tender offer could deliver an immediate liquidity event and potential premium for LVTX shareholders.
• Strategic validation: XOMA’s interest underscores perceived value in LAVA’s γδ T-cell engager platform.

Negative

• No price or premium disclosed, preventing valuation assessment.
• Multiple deal risks cited (regulatory, legal, competing bids, CVR conditions) could delay or derail completion.

Insights

M&A Specialist

TL;DR – Intent to acquire LVTX disclosed; valuation and closing certainty still unknown, so market impact is preliminary.

This Schedule TO-C merely satisfies Rule 14d pre-commencement disclosure. It signals XOMA’s strategic move to consolidate royalty assets through a full cash tender (terms pending). Because pricing, premium and financing are absent, investors cannot yet gauge accretion or premium level. Customary risks—competing offers, regulatory delays, CVR payout triggers—underline deal uncertainty. For now, the filing is procedurally important but not yet economically definitive.

Biotechnology Equity Analyst

TL;DR – Potential liquidity event for LVTX holders, but scientific and CVR value still opaque.

LAVA focuses on bispecific γδ T-cell engagers; XOMA’s interest suggests perceived pipeline value, yet purchase price and CVR milestones are undisclosed. Without those, investors cannot judge whether the bid reflects fair asset value or offers meaningful upside to current trading levels. Given multiple clinical inflection points ahead, competing bids remain possible. Overall, disclosure is neutral until economics surface.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

(Rule 14d-100)

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

LAVA Therapeutics N.V.

(Name of Subject Company (Issuer))

XOMA ROYALTY CORPORATION

(Name of Filing Persons (Offeror 1))

Ordinary Shares, Par Value €0.12 Per Share

(Title of Class of Securities)

N51517105

(CUSIP Number of Class of Securities)

Owen Hughes

XOMA Royalty Corporation

2200 Powell Street, Suite 310

Emeryville, California 94608

Tel. (510) 204-7200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

Copies to:

Ryan A. Murr

Branden C. Berns

Gibson, Dunn & Crutcher LLP

One Embarcadero Center Suite 2600

San Francisco, CA 94111

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 13d-1(d) (Cross-Border Third-Party Tender Offer)

This filing relates solely to preliminary communications made before the commencement of a planned tender offer (the “Offer”) by XOMA Royalty Corporation, a Nevada corporation (“Buyer”), to purchase all of the issued and outstanding ordinary shares, par value €0.12 per share (“Shares”), of Lava Therapeutics N.V., a Dutch public limited liability company (“LAVA”), to be commenced pursuant to the Share Purchase Agreement, dated as of August 3, 2025, among Buyer and LAVA (the “Purchase Agreement”).

The press release filed herewith as Exhibit 99.1 is neither an offer to purchase nor a solicitation of an offer to sell securities. The Offer for the Shares described in this filing has not commenced. At the time the Offer is commenced, the Buyer will file a tender offer statement on Schedule TO with the Securities and Exchange Commission (“SEC”), and LAVA will file a solicitation/recommendation statement on Schedule 14D-9, with respect to the Offer.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements related to the Buyer and LAVA and the acquisition by the Buyer of LAVA, including express or implied forward-looking statements about the future operations and performance of LAVA and Buyer. These forward-looking statements are within the meaning of U.S. federal securities laws, including, without limitation, statements regarding the anticipated timing of and closing of the proposed Offer and related transactions contemplated by the Purchase Agreement (collectively referred to as the “transactions”). The words “anticipate,” “approximately,” “look to,” “plan,” “expect,” “may,” “will,” “could” or “should,” the negative of these terms or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. The Buyer cautions that a number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Any forward-looking statements in this communication are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this communication, including, without limitation, the impact of actions of other parties with respect to the transactions; the possibility that competing offers will be made; the outcome of any legal proceedings that have been or could be instituted against the Buyer , LAVA or their respective directors; the risk that the transactions may not be completed in a timely manner, or at all, which may adversely affect LAVA’s or Buyer’s respective businesses and the price of their respective shares of capital stock; the failure to satisfy all of the closing conditions of the transactions contemplated by the Purchase Agreement; the occurrence of the events giving rise to payments under the Contingent Value Rights (“CVR”) Agreement; the occurrence of any event, change or other circumstance that could give rise to the termination of the Purchase Agreement; the effect of the announcement or pendency of the transactions on LAVA’s and Buyer’s respective businesses and operating results; risks that the transactions may disrupt LAVA’s or Buyer’s respective current plans and business operations; risks related to the diverting of management’s attention from LAVA’s and Buyer’s respective ongoing business operations; general economic and market conditions and the other risks identified in LAVA’s and Buyer’s respective filings with the SEC and subsequent filings with the SEC. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transactions and/or LAVA and the Buyer’s ability to successfully complete the transactions and, with respect to any CVR payment amounts, the consideration ultimately paid to LAVA shareholders (including whether any payments will be payable at all). In addition, unlisted factors may present significant additional obstacles to the realization of forward-looking statements. The Buyer cautions investors not to place undue reliance on any forward-looking statements. Any forward-looking statements contained in this communication represent the Buyer’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Buyer disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Additional Information and Where to Find It

The tender offer for the Shares of LAVA referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that the Buyer will file with the SEC. At the time the tender offer is commenced, the Buyer will file tender offer materials on Schedule TO, and, thereafter, LAVA will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. The Offer will be made only pursuant to the tender offer materials (including an offer to purchase, a related letter of transmittal and certain other tender offer documents) filed with the SEC.

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. HOLDERS OF LAVA’S ORDINARY SHARES ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LAVA’S ORDINARY SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.

The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of LAVA’s ordinary shares at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov or by accessing the Investor Relations section of Buyer’s website at https://investors.xoma.com/.

EXHIBIT INDEX.

Index No.
99.1		Joint Press Release issued by XOMA Royalty Corporation and LAVA Therapeutics N.V. on August 4, 2025.

FAQ

What is XOMA Royalty Corp.'s plan for LAVA Therapeutics (LVTX)?

XOMA intends to launch a cash tender offer to acquire 100 % of LVTX shares under a Purchase Agreement dated 3 Aug 2025.

Has the LVTX tender offer started?

No. The Schedule TO-C is a pre-commencement notice; the offer will begin only after XOMA files a full Schedule TO.

Where can shareholders find the official tender documents?

Once filed, they will be free at www.sec.gov and on XOMA’s investor relations website.

Are LVTX shareholders required to act now?

No action is required until the formal offer documents are available and the tender period opens.

What risks could prevent the acquisition from closing?

Cited risks include competing bids, regulatory hurdles, legal challenges, unmet closing conditions and CVR payment uncertainties.